newli
identifi
novel
coronaviru
caus
laboratoryconfirm
human
infect
includ
death
pose
seriou
threat
human
health
current
howev
specif
antivir
treatment
vaccin
consid
rel
high
ident
receptorbind
domain
rbd
sarscov
urgent
assess
crossreact
antisar
cov
antibodi
spike
protein
could
import
implic
rapid
develop
vaccin
therapeut
antibodi
report
first
time
sarscovspecif
human
monoclon
antibodi
could
bind
potent
rbd
kd
nm
epitop
overlap
bind
site
within
rbd
result
suggest
may
potenti
develop
candid
therapeut
alon
combin
neutral
antibodi
prevent
treatment
infect
interestingli
potent
sarscovspecif
neutral
antibodi
eg
target
bind
site
sarscov
fail
bind
spike
protein
impli
differ
rbd
sarscov
critic
impact
crossreact
neutral
antibodi
still
necessari
develop
novel
monoclon
antibodi
could
bind
specif
rbd
recent
novel
coronaviru
temporarili
name
novel
coronaviru
emerg
wuhan
china
februari
result
total
laboratoryconfirm
human
infect
china
includ
death
export
case
countri
outsid
china
http
wwwwhointemerg
current
vaccin
effect
antivir
treatment
infect
base
phylogenet
analysi
gisaid
access
belong
lineag
b
betacoronaviru
share
high
sequenc
ident
bat
human
sever
acut
respiratori
syndrom
coronavirusrel
coronaviru
sarsrcov
bat
sarslik
coronaviru
slcov
figur
previou
studi
number
potent
monoclon
antibodi
sar
coronaviru
sarscov
identifi
antibodi
target
spike
protein
sarscov
slcov
type
transmembran
glycoprotein
mediat
entranc
human
respiratori
epitheli
cell
interact
cell
surfac
receptor
angiotensinconvert
enzym
specif
amino
acid
length
receptor
bind
domain
rbd
within
protein
critic
target
neutral
antibodi
antibodi
recogn
differ
epitop
rbd
eg
sarscov
neutral
antibodi
bound
noncompetit
sarscov
rbd
neutral
viru
synergist
fashion
predict
conform
rbd
well
complex
structur
sever
neutral
antibodi
found
model
result
support
interact
rbd
certain
sarscov
antibodi
figur
b
could
due
rel
high
ident
rbd
sarscov
figur
c
instanc
residu
rbd
sarscov
make
polar
interact
neutral
antibodi
indic
complex
crystal
structur
invari
conserv
rbd
figur
structur
rbd
form
salt
bridg
concordantli
electrostat
interact
also
observ
model
form
rbd
analysi
suggest
sarscovspecif
monoclon
antibodi
may
effect
neutral
contrast
interact
antibodi
rbd
decreas
significantli
due
lack
salt
bridg
form
respect
furthermor
residu
rbd
sarscov
conserv
rbd
figur
c
unlik
antibodi
could
effect
recogn
therefor
urgent
experiment
determin
crossreact
antisarscov
antibodi
spike
protein
could
import
implic
rapid
develop
vaccin
therapeut
antibodi
studi
first
express
purifi
rbd
protein
also
predict
conform
rbd
complex
put
receptor
human
comparison
interact
complex
sarscov
rbd
homolog
model
rbd
reveal
similar
bind
mode
data
shown
complex
loop
loop
form
extens
contact
includ
least
seven
pair
hydrogen
bond
receptor
notabl
forth
helix
sarscov
rbd
build
salt
bridg
hydrogen
bond
howev
arginin
sarscov
rbd
asparagin
mutat
rbd
abolish
strong
polar
interact
may
induc
decreas
bind
affin
rbd
receptor
interestingli
lysin
rbd
replac
valin
sarscov
rbd
form
extra
salt
bridg
may
recov
bind
abil
data
indic
rbd
protein
may
bind
similar
affin
sarscov
rbd
inde
measur
bind
rbd
human
biolay
interferometri
bind
bli
assay
found
rbd
bound
potent
calcul
affin
k
rbd
human
nm
figur
f
compar
sarscov
spike
protein
human
nm
result
indic
could
potenti
receptor
new
coronaviru
express
rbd
protein
function
next
express
purifi
sever
repres
sarscovspecif
antibodi
report
target
rbd
possess
potent
neutral
activ
includ
well
merscovspecif
human
monoclon
antibodi
develop
laboratori
measur
bind
abil
rbd
elisa
figur
e
surprisingli
found
antibodi
show
evid
bind
rbd
confirm
result
measur
bind
kinet
use
bli
irrelev
antibodi
use
neg
control
similarli
antibodi
predict
bind
rbd
figur
show
slight
bind
highest
measur
concentr
studi
need
solv
highresolut
structur
rbd
understand
could
recogn
antibodi
notabl
one
sarscovspecif
antibodi
found
bind
potent
rbd
determin
elisa
bli
figur
e
f
follow
faston
k
ms
slowoff
k
bind
kinet
result
k
nm
figur
f
antibodi
isol
blood
convalesc
sar
patient
compet
antibodi
bind
recombin
protein
elucid
bind
epitop
measur
competit
human
bind
rbd
streptavidin
biosensor
label
biotinyl
rbd
satur
human
solut
follow
addit
test
antibodi
presenc
shown
figur
g
antibodi
show
competit
bind
rbd
result
suggest
distinct
two
sarscov
antibodi
recogn
epitop
overlap
bind
site
rbd
rbd
differ
larg
sarscov
cterminu
residu
figur
c
result
impli
differ
result
drastic
chang
capabl
engag
receptor
critic
impact
crossreact
neutral
antibodi
potent
sarscovspecif
neutral
antibodi
eg
target
receptor
bind
site
sarscov
fail
bind
spike
protein
indic
necessari
develop
novel
monoclon
antibodi
could
bind
specif
rbd
interestingli
report
antibodi
complet
neutral
wildtyp
sarscov
escap
virus
concentr
escap
variant
could
gener
furthermor
mixtur
neutral
sarscov
synergist
fashion
recogn
differ
epitop
rbd
result
suggest
potenti
develop
candid
therapeut
alon
combin
neutral
antibodi
prevent
treatment
infect
expect
crossreact
antibodi
sarscov
coronavirus
identifi
soon
facilit
develop
effect
antivir
therapeut
vaccin
potenti
conflict
interest
report
author
